No treatment is given

OTHER4 trials

Sponsors

Novo Nordisk A/S

Conditions

Idiopathic Short StatureLiver DiseaseMASLD/MASHObesityOverweight

Unknown Phase

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

TerminatedNCT05894876

Novo Nordisk A/SIdiopathic Short Stature

Start: 2024-04-29End: 2025-03-21Updated: 2025-12-12

Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender

CompletedNCT06260696

Novo Nordisk A/SObesity, Overweight

Start: 2023-08-10End: 2023-10-05Updated: 2024-02-15

Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians

RecruitingNCT07682363

Novo Nordisk A/SLiver Disease

Start: 2026-06-03End: 2027-02-23Target: 470Updated: 2026-07-02

Korean Real-world Study on MASLD/MASH Outcomes.

Active, not recruitingNCT07739901

Novo Nordisk A/SMASLD/MASH

Start: 2026-07-13End: 2026-09-30Target: 10000Updated: 2026-07-31